The report encapsulates a comprehensive overview of the network’s achievements, breakthroughs, and collaborations in the field of glycomics throughout the past year.
Within the report, readers will gain insight into the cutting-edge research and advancements made by GlycoNet, a collaborative effort involving scientists, researchers, and experts from academia, industry, and government institutions. It delves into the pioneering discoveries in glycobiology, highlighting the innovative applications and technologies that have emerged within the network.
Senator Paula Simons recently toured GlycoNet at the University of Alberta, exploring the realm of glycomics. The visit highlighted GlycoNet’s pivotal role in advancing glycomics and its transformative impact across One Health domains, underlined by discussions with GlycoNet’s CEO, Dr. Elizabeth Nanak.
The tour of cutting-edge labs showcased passionate researchers driving innovation in glycomics, and interactions with start-ups like 48Hour Discovery shed light on drug discovery advancements. This visit emphasized the value of such engagements, illustrating the shared commitment to a thriving future and the potential for collaborative efforts to elevate healthcare and nurture a diverse bioeconomy.
Five glycomics projects have been awarded funding to develop new tools, diagnostics and therapeutics to improve health for Canadians.
A significant gathering of researchers, industry experts, and rising stars in glycomics recently took place in Edmonton, Alberta with the Honourable Randy Boissonnault, focusing on advancements and current trends in the field.
PlantForm Corporation has teamed up with a University of British Columbia research group led by Dr. Joerg Bohlmann to develop a novel plant-based treatment option for Type-2 diabetes and obesity, with support from GlycoNet.
This partnership will launch the clinical trial of a new blood test to perfect early detection and diagnosis of clinically significant prostate cancer.
This investment will support state-of-the-art glycomics research that focuses on different aspects of One Health—human, animal and environmental health.
Glycomics in Canada receives crucial funding boost to further life-saving research and biotechnology development.
This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.